<PAGE>
===============================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                                ----------------


                                    FORM 10-Q


(MARK ONE)

[X]   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934
        FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2003

                                       OR

[ ]   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934

          FOR THE TRANSITION PERIOD FROM _____________ TO______________

                        COMMISSION FILE NUMBER 000-31167

                          GENENCOR INTERNATIONAL, INC.
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
                                ----------------

<TABLE>
<CAPTION>
                           DELAWARE                                                         16-1362385
<S>                                                                                  <C>
               (STATE OR OTHER JURISDICTION OF                                           (I.R.S. EMPLOYER
                INCORPORATION OR ORGANIZATION)                                        IDENTIFICATION NUMBER)
</TABLE>


                               925 PAGE MILL ROAD
                           PALO ALTO, CALIFORNIA 94304
                                 (650) 846-7500
                   (ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE
   NUMBER, INCLUDING AREA CODE, OF REGISTRANT'S PRINCIPAL EXECUTIVE OFFICES)

                                  ------------

     INDICATE BY CHECK MARK WHETHER THE REGISTRANT (1) HAS FILED ALL REPORTS
REQUIRED TO BE FILED BY SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934 DURING THE PRECEDING 12 MONTHS (OR FOR SUCH SHORTER PERIOD THAT THE
REGISTRANT WAS REQUIRED TO FILE SUCH REPORT(S), AND (2) HAS BEEN SUBJECT TO SUCH
FILING REQUIREMENTS FOR THE PAST 90 DAYS

                                YES [ X ] NO [ ]


              INDICATE BY CHECK MARK WHETHER THE REGISTRANT IS AN ACCELERATED
FILER (AS DEFINED IN RULE 12b-2 OF THE EXCHANGE ACT).

                                YES [ X ] NO [ ]
                                  ------------

     INDICATE THE NUMBER OF SHARES OUTSTANDING OF EACH OF THE ISSUER'S CLASSES
OF COMMON STOCK, AS OF THE LATEST PRACTICABLE DATE.


<TABLE>
                     CLASS                                        NUMBER OF SHARES OUTSTANDING AT JULY 31, 2003
<S>                                                                              <C>
     COMMON STOCK, PAR VALUE $0.01 PER SHARE                                       58,980,489
</TABLE>


<PAGE>


                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                                                    PAGE
                                                                                                                    ----
<S>                                                                                                                 <C>
PART I.   FINANCIAL INFORMATION
     Item 1.  Financial Statements:
                 Condensed Consolidated Unaudited Balance Sheets as of June 30, 2003 and December 31, 2002.......      4
                 Condensed Consolidated Unaudited Statements of Operations for the three and six months
                   ended June 30, 2003 and 2002..................................................................      5
                 Condensed Consolidated Unaudited Statements of Cash Flows for the six months ended
                   June 30, 2003 and 2002........................................................................      6
                 Notes to Condensed Consolidated Unaudited Financial Statements..................................      7
     Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations..............      14
     Item 3.  Quantitative and Qualitative Disclosures About Market Risk.........................................      27
     Item 4.  Controls and Procedures............................................................................      27

PART II.  OTHER INFORMATION
     Item 1.  Legal Proceedings..................................................................................      28
     Item 2.  Changes in Securities and Use of Proceeds..........................................................      28
     Item 3.  Defaults Upon Senior Securities....................................................................      28
     Item 4.  Submission of Matters to a Vote of Security Holders................................................      29
     Item 5.  Other Information..................................................................................      29
     Item 6.  Exhibits and Reports on Form 8-K...................................................................      30

SIGNATURES.......................................................................................................      31
INDEX to EXHIBITS................................................................................................      32
</TABLE>




                                       2
<PAGE>


     This Report contains forward-looking statements as defined by the Private
Securities Litigation Reform Act of 1995. These include statements concerning
plans, objectives, goals, strategies, future events or performance and all other
statements which are other than statements of historical fact, including without
limitation, statements containing the words "believes," "anticipates,"
"expects," "estimates," "projects," "will," "may," "might" and words of a
similar nature. The forward-looking statements contained in this Report reflect
the Company's current beliefs and expectations on the date of this Report.
Actual results, performance or outcomes may differ materially from those
expressed in the forward-looking statements. Some of the important factors
which, in the view of the Company, could cause actual results to differ from
those expressed in the forward-looking statements are discussed in Part I, Item
2 of this Report and in the Company's 2002 Annual Report on Form 10-K. The
Company disclaims any obligation to publicly announce any revisions to these
forward-looking statements to reflect facts or circumstances of which the
Company becomes aware after the date hereof.

     Unless otherwise specified, all references in this Report to the "Company",
"we", "us", "our", and "ourselves" refer to Genencor International, Inc. and its
subsidiaries collectively, as appropriate in the context of the disclosure.




                                       3
<PAGE>

PART I.  FINANCIAL INFORMATION

ITEM 1.     FINANCIAL STATEMENTS


                  GENENCOR INTERNATIONAL, INC. AND SUBSIDIARIES

                 CONDENSED CONSOLIDATED UNAUDITED BALANCE SHEETS
                  (AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA)



<TABLE>
<CAPTION>
                                                                                             JUNE 30,         DECEMBER 31,
                                                                                               2003               2002
                                                                                               ----               ----
<S>                                                                                     <C>                 <C>
    ASSETS
    Current assets:
       Cash and cash equivalents.....................................................   $      155,381      $      169,001
       Trade accounts receivable, net ...............................................           56,638              51,576
       Inventories...................................................................           55,573              54,215
       Other current assets..........................................................           41,439              27,569
                                                                                        --------------      --------------
           Total current assets......................................................          309,031             302,361
    Property, plant and equipment, net...............................................          220,162             217,110
    Goodwill.........................................................................           29,379              29,384
    Intangible assets, net...........................................................           44,070              45,898
    Other assets.....................................................................           63,862              60,169
                                                                                        --------------      ---------------
           Total assets..............................................................   $      666,504      $      654,922
                                                                                        ==============      ==============

    LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY
    Current liabilities:
       Notes payable.................................................................   $        8,033      $        7,942
       Current maturities of long-term debt..........................................           28,291              28,291
      Accounts payable and accrued expenses..........................................           45,577              47,549
      Other current liabilities......................................................           14,265              15,536
                                                                                        --------------      --------------
           Total current liabilities.................................................           96,166              99,318
    Long-term debt...................................................................           56,816              84,897
    Other long-term liabilities......................................................           38,823              32,700
                                                                                        --------------      --------------
           Total liabilities.........................................................          191,805             216,915
                                                                                        --------------      --------------
    Redeemable preferred stock:
         7 1/2% cumulative series A preferred stock, without par value, authorized
         1 shares, 1 shares issued and outstanding...................................          173,388             169,750
                                                                                        --------------      --------------
    Stockholders' equity:
      Common stock, par value $0.01 per share, 200,000 shares authorized, 60,578
         and 60,251 shares issued at June 30, 2003 and
         December 31, 2002, respectively.............................................              606                 602
      Additional paid-in capital.....................................................          352,880             349,579
      Treasury stock, 1,780 shares at cost at June 30, 2003 and
         December 31, 2002...........................................................          (21,030)            (21,030)
      Deferred stock-based compensation..............................................           (1,283)             (1,164)
      Accumulated deficit............................................................           (4,443)            (14,944)
      Accumulated other comprehensive loss...........................................          (25,419)            (44,786)
                                                                                        --------------      --------------
           Total stockholders' equity................................................          301,311             268,257
                                                                                        --------------      --------------
           Total liabilities, redeemable preferred stock and stockholders' equity....   $      666,504      $      654,922
                                                                                        ==============      ==============
</TABLE>



          The accompanying notes are an integral part of the condensed
                  consolidated unaudited financial statements.



                                       4
<PAGE>



                  GENENCOR INTERNATIONAL, INC. AND SUBSIDIARIES

            CONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF OPERATIONS
                  (AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA)

<TABLE>
<CAPTION>



                                                           THREE MONTHS ENDED                         SIX MONTHS ENDED
                                                                JUNE 30,                                  JUNE 30,
                                                                --------                                  --------
                                                       2003               2002                   2003              2002
                                                       ----               ----                   ----              ----
<S>                                                <C>                <C>                    <C>               <C>
Revenues:
  Product revenue................................  $     89,744       $     85,470           $    179,782      $    161,018
  Fees and royalty revenues......................         6,603              5,162                 12,226            10,424
                                                   ------------       ------------           ------------      ------------
       Total revenues............................        96,347             90,632                192,008           171,442
Operating expenses:
  Cost of products sold..........................        51,786             46,096                102,627            88,214
  Research and development.......................        16,833             17,310                 33,293            32,942
  Sales, marketing and business development......         7,902              8,566                 15,601            15,708
  General and administrative.....................         7,982              8,264                 15,783            16,296
  Amortization of intangible assets..............         1,498              1,327                  2,890             2,634
  Restructuring and related charges                          --                 85                     --            16,379
  Other expense/(income).........................            54             (2,110)                   759            (3,457)
                                                   ------------       ------------           -------------     ------------
       Total operating expenses..................        86,055             79,538                170,953           168,716
                                                   ------------       ------------           ------------      ------------
Operating income.................................        10,292             11,094                 21,055             2,726
Non operating expenses/(income):
  Investment expense.............................         1,018                 --                  1,018                --
  Interest expense...............................         1,569              2,044                  3,589             4,564
  Interest income................................        (1,558)            (1,311)                (2,403)           (2,712)
                                                   ------------       ------------           ------------      -------------
       Total non operating expenses/(income).....         1,029                733                  2,204             1,852
                                                   ------------       ------------           ------------      ------------
Income before income taxes.......................         9,263             10,361                 18,851               874
Provision for/(benefit from) income taxes........         1,644              5,578                  4,712            (2,850)
                                                   ------------       ------------           ------------      ------------
Net income.......................................  $      7,619       $      4,783           $     14,139      $      3,724
                                                   ============       ============           ============      ============
Net income available to holders of common
 stock...........................................  $      5,800       $      2,964           $     10,501      $         86
                                                   ============       ============           ============      ============
  Earnings per common share:
       Basic.....................................  $       0.10       $       0.05           $       0.18      $       0.00
                                                   ============       ============           ============      ============
       Diluted...................................  $       0.10       $       0.05           $       0.18      $       0.00
                                                   ============       ============           ============      ============
  Weighted average common shares:
       Basic.....................................        58,570             59,679                 58,534            59,668
                                                   ============       ============           ============      ============
       Diluted...................................        60,230             60,147                 59,515            60,132
                                                   ============       ============           ============      ============

</TABLE>



          The accompanying notes are an integral part of the condensed
                  consolidated unaudited financial statements.



                                       5
<PAGE>




                  GENENCOR INTERNATIONAL, INC. AND SUBSIDIARIES

            CONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF CASH FLOWS
                             (AMOUNTS IN THOUSANDS)

<TABLE>
<CAPTION>
                                                                                           SIX MONTHS ENDED
                                                                                               JUNE 30,
                                                                                     2003                   2002
                                                                                     ----                   ----

<S>                                                                         <C>                     <C>
Cash flows from operating activities:
  Net income...........................................................     $         14,139        $          3,724
  Adjustments to reconcile net income to net cash provided by
    operating activities:
      Depreciation and amortization....................................               17,702                  16,195
      Amortization of deferred stock-based compensation................                  554                   1,567
      Loss on disposition of property, plant
          and equipment................................................                  521                     362
      Loss from impairment of investment in
          marketable equity securities.................................                1,018                       -
      Non-cash portion of restructuring and related charges ...........                    -                   9,225
      (Increase) decrease in operating assets:
         Trade accounts receivable.....................................               (1,648)                 (3,401)
         Inventories...................................................                2,307                  (3,897)
         Other assets..................................................              (13,260)                 (6,463)
      Decrease in operating liabilities:
         Accounts payable and accrued expenses.........................               (4,491)                 (6,189)
         Other liabilities.............................................                 (963)                   (936)
                                                                            ----------------        ----------------
         Net cash provided by operating activities.....................               15,879                  10,187
                                                                            ----------------        ----------------
Cash flows from investing activities:
  Purchases of property, plant and equipment...........................              (10,553)                 (5,852)
  Purchases of intangible assets.......................................                    -                    (100)
  Proceeds from sale of business.......................................                1,145                       -
  Payment to acquire equity securities.................................                    -                  (3,000)
  Acquisition of business, net of cash acquired........................                    -                 (35,809)
                                                                            -----------------       ----------------
         Net cash used in investing activities.........................               (9,408)                (44,761)
                                                                            -----------------       ----------------
Cash flows from financing activities:
  Proceeds from exercise of stock options..............................                1,876                     349
  Proceeds from employee stock purchase plan...........................                  732                     795
  Net proceeds (payments) on revolving credit facility.................                   91                     (78)
  Net payments on notes payable of foreign affiliate ..................                    -                     (82)
  Payment of long-term debt............................................              (28,123)                (28,000)
                                                                            ----------------        ----------------
         Net cash used in financing activities.........................              (25,424)                (27,016)
                                                                            ----------------        ----------------
Effect of exchange rate changes on cash................................                5,333                   6,682
                                                                            ----------------        ----------------
Net decrease in cash and cash equivalents..............................              (13,620)                (54,908)
Cash and cash equivalents -- beginning of period.......................              169,001                 215,023
                                                                            ----------------        ----------------
Cash and cash equivalents -- end of period.............................     $        155,381        $        160,115
                                                                            ================        ================
</TABLE>

          The accompanying notes are an integral part of the condensed
                  consolidated unaudited financial statements.


                                       6
<PAGE>




                  GENENCOR INTERNATIONAL, INC. AND SUBSIDIARIES

         NOTES TO CONDENSED CONSOLIDATED UNAUDITED FINANCIAL STATEMENTS
                  (AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA)



1 -- BASIS OF PRESENTATION

     The condensed consolidated unaudited financial statements should be read in
conjunction with the Company's audited consolidated financial statements and
related footnotes for the year ended December 31, 2002, as included in the
Company's Annual Report on Form 10-K. These interim financial statements have
been prepared in conformity with the rules and regulations of the U.S.
Securities and Exchange Commission. Certain disclosures normally included in
financial statements prepared in conformity with accounting principles generally
accepted in the United States of America have been condensed or omitted pursuant
to such rules and regulations pertaining to interim financial statements. In the
opinion of management, all adjustments (consisting of normal recurring
adjustments) necessary for fair presentation of the interim financial statements
have been included therein. The results of operations of any interim period are
not necessarily indicative of the results of operations for the full year.


2 -- NEW ACCOUNTING PRONOUNCEMENTS

     In April 2003, the Financial Accounting Standards Board (FASB) issued
Statement of Financial Accounting Standards (SFAS) No. 149, "Amendment of
Statement 133 on Derivative Instruments and Hedging Activities." This Statement
amends SFAS No. 133 for decisions made (1) as part of the Derivatives
Implementation Group process that effectively required amendments to SFAS No.
133, (2) in connection with other FASB projects dealing with financial
instruments, and (3) in connection with implementation issues raised in relation
to the application of the definition of a derivative. This Statement is
effective for contracts entered into or modified after June 30, 2003 and for
hedging relationships designated after June 30, 2003. All provisions of this
Statement are to be applied prospectively. The Company will apply the provisions
of this statement as of July 1, 2003. The adoption of SFAS No. 149 will not have
a material impact on the Company's financial position or results of operations.

     In May 2003, the FASB issued SFAS No. 150, "Accounting for Certain
Financial Instruments with Characteristics of both Liabilities and Equity." This
statement establishes standards for how the Company classifies and measures
certain financial instruments with characteristics of both liabilities and
equity. It requires that the Company classify a financial instrument within its
scope as a liability. Some of the provisions of this Statement are consistent
with the current definition of liabilities in FASB Concepts Statement No. 6,
"Elements of Financial Statements." The remaining provisions of this Statement
are consistent with the FASB's proposal to revise that definition to encompass
certain obligations that a reporting entity can or must settle by issuing its
own equity shares, depending on the nature of the relationship established
between the holder and the issuer. This Statement is effective for financial
instruments entered into or modified after May 31, 2003 and otherwise is
effective at the beginning of the first interim period beginning after June 15,
2003. The Company is currently assessing the impact of this new standard on its
financial statements.


3 -- EARNINGS PER SHARE

     SFAS No. 128, "Earnings per Share," requires the disclosure of basic
and diluted earnings per share. Basic earnings per share is computed based on
the weighted average number of common shares outstanding during the period. In
arriving at net income available to holders of common stock, undeclared and
unpaid dividends on redeemable preferred stock of $1,819 and $3,638 were
deducted from net income for each quarter presented and for each six-month
period presented, respectively.

     Diluted earnings per common share reflects the potential dilution that
could occur if dilutive securities and other contracts to issue common stock
were exercised or converted into common stock or resulted in the issuance of
common stock that then shared in the net income available to holders of common
stock of the Company. As a result of stock options outstanding under the
Company's 2002 Omnibus Incentive Plan, successor to the Company's Stock Option
and Stock Appreciation Right Plan, there were dilutive securities for the three
and sixth months ended June 30, 2003 and 2002. The


                                       7
<PAGE>

weighted-average impact of these has been reflected in the calculation of
diluted earnings per common share for the respective periods presented.

     The following table reflects the calculation of basic and diluted earnings
per common share for the three and sixth months ended June 30, 2003 and 2002:
<TABLE>
<CAPTION>
                                                  THREE MONTHS ENDED                  SIX MONTHS ENDED
                                                        JUNE 30,                         JUNE 30,
                                                       --------                         --------

                                               2003            2002              2003            2002
                                                ----            ----              ----            ----
<S>                                           <C>             <C>             <C>             <C>
Net income ............................       $  7,619        $  4,783        $ 14,139        $  3,724
   Less: Accrued dividends on preferred
   stock ..............................         (1,819)         (1,819)         (3,638)         (3,638)
                                              --------        --------        --------        --------
Net income available to holders of
   common stock .......................       $  5,800        $  2,964        $ 10,501        $     86
                                              ========        ========        ========        ========

Weighted average common shares:
   Basic ..............................         58,570          59,679          58,534          59,668
   Effect of stock options ............          1,660             468             981             464
                                              --------        --------        --------        --------
   Diluted ............................         60,230          60,147          59,515          60,132
                                              ========        ========        ========        ========
Earnings per common share:
   Basic ..............................       $   0.10        $   0.05        $   0.18        $   0.00
                                              ========        ========        ========        ========
   Diluted ............................       $   0.10        $   0.05        $   0.18        $   0.00
                                              ========        ========        ========        ========
</TABLE>



4 -- STOCK-BASED COMPENSATION

     The Company adopted the disclosure provisions of SFAS No. 148 effective
January 1, 2003. The Company uses the intrinsic value method to account for
stock-based employee compensation in accordance with Accounting Principles Board
(APB) Opinion No. 25 "Accounting for Stock Issued to Employees" and has no
current plans to convert to the fair value method.

     On a pro forma basis, had compensation cost for the Company's stock option
plans been determined based on the weighted average fair value at the grant
date, the Company's net income and earnings per share would have been reduced to
the pro forma amounts shown below for the three and sixth months ended June 30,
2003 and 2002:

<TABLE>
<CAPTION>
                                                                     THREE MONTHS ENDED                   SIX MONTHS ENDED
                                                                           JUNE 30,                          JUNE 30,
                                                                           --------                          --------
                                                                    2003            2002             2003                 2002
                                                                    ----            ----             ----                 ----
<S>                                                            <C>               <C>              <C>            <C>
Net income available to holders of common stock -
   as reported.............................................     $     5,800      $     2,964      $     10,501      $        86
Add: Stock-based employee compensation expense
   included in reported net income available,
   net of related tax .....................................             124              218               286              538
Deduct: Total stock-based employee compensation
   expense determined under fair value based
   method for all awards, net of related tax effect........          (1,324)          (1,340)           (2,624)          (2,278)
                                                                  ----------       ----------       -----------        ---------
   Net income available to holders of common stock -
     pro forma ............................................     $     4,600      $      1,842     $      8,163      $     (1,654)
                                                                  ==========       ==========        ==========        =========

  Basic - as reported .....................................     $       0.10     $       0.05     $        0.18     $       0.00
  Basic - pro forma .......................................     $       0.08     $       0.03     $        0.14     $      (0.03)
  Diluted - as reported ...................................     $       0.10     $       0.05     $        0.18     $       0.00
  Diluted - pro forma .....................................     $       0.08     $       0.03     $        0.14     $      (0.03)
</TABLE>

     The pro forma figures in the preceding table may not be representative of
pro forma amounts in future quarters.




                                       8
<PAGE>


     On June 6, 2003, the Company granted 47 shares of restricted common stock
to certain executive officers. These restricted shares were granted at fair
market value at the date of grant and the restrictions on these awards expire
three years from the grant date. Deferred compensation of $675 was recorded in
connection with these awards and was determined based on the number of granted
restricted shares and the fair market value on the grant date. This amount was
recorded as a component of stockholders' equity and will be amortized as a
charge to operations over the vesting period of the awards.


5 -- INVENTORIES

Inventories consist of the following:

<TABLE>
<CAPTION>
                                     JUNE 30,     DECEMBER 31,
                                      2003           2002
                                      ----           ----
<S>                                 <C>            <C>
Raw materials ..................... $ 8,686        $ 8,373
Work-in-progress...................   7,876          8,003
Finished goods ....................  39,011         37,839
                                    -------        -------
  Inventories ..................... $55,573        $54,215
                                    =======        =======
</TABLE>

     During the quarter ended June 30, 2003, the Company sustained damage to its
finished bioproduct inventory as a result of an accident in a third party
warehouse in Rotterdam, the Netherlands. While there has been no material
interruption in product flow to customers, the Company reduced its inventories
by $7,487 to reflect the estimated amount of product that was lost. In addition,
$1,041 of other costs were incurred as a result of the accident. These amounts
have been recorded in other current assets as a receivable from the Company's
insurer. Certain reduced profits and additional costs, such as production
inefficiencies, additional freight and use of overtime are reflected in the
results of operations during the quarter ended June 30, 2003. While the Company
believes that these reduced profits and additional costs will be subject to
insurance recovery, the Company is unable to estimate the ultimate recovery at
this time.

6 -- GOODWILL AND OTHER INTANGIBLE ASSETS

     The Company adopted the provisions of SFAS No. 142 effective as of January
1, 2002. Accordingly, the Company no longer amortizes goodwill or other
intangible assets with indefinite useful lives. The Company has identified such
other indefinite-lived intangible assets to include certain previously acquired
technology. The Company will periodically evaluate its indefinite-lived
intangible assets for impairment in accordance with the provisions of SFAS No.
142. The Company also has other intangible assets, such as patents, licenses,
and customer lists, which will continue to be amortized using the straight-line
method. These assets are expected to have no residual value once they are fully
amortized.

     The following table summarizes the changes in each major class of
intangible assets from December 31, 2002 through June 30, 2003:

<TABLE>
<CAPTION>
                                                                           INTANGIBLE ASSETS                        GOODWILL
                                                      --------------------------------------------------------    ------------
                                                                                OTHER
                                                                              AMORTIZABLE
                                                         TECHNOLOGY             ASSETS               TOTAL
                                                      ---------------      ---------------       -------------
<S>                                                     <C>                    <C>                <C>              <C>
Balances, December 31, 2002                             $    15,617            $ 65,429           $    81,046      $   29,384
Foreign currency translation
  and other adjustments.....................                      -               1,705                 1,705              (5)
                                                        -----------          ----------           -----------      ----------
Balances, June 30, 2003.....................            $    15,617              67,134                82,751      $   29,379
                                                        ===========                                                ==========
Less: Accumulated
  amortization..............................                                    (38,681)              (38,681)
                                                                              ---------           -----------
   Intangible assets, net...................                                   $ 28,453           $    44,070
                                                                              =========           ===========
</TABLE>

     In conjunction with the acquisition discussed in Note 10, the Company
acquired certain intangible assets on December 31, 2002. The Company is
currently in the process of segregating these intangible assets among the major
classes. As such, the estimated value of these intangible assets has been
included in other amortizable intangible assets and will be segregated among the
major classes once the Company completes its allocation of the purchase price.


                                       9
<PAGE>


     The foreign currency translation and other adjustments of $1,705 consists
of $2,802 of foreign currency translation. Also included are additional
acquisition costs of $48 to acquire the assets and the sale of certain acquired
assets for $1,145, which were sold at fair market value resulting in no gain or
loss on the sale.

     Estimated fiscal year amortization expense is as follows:

<TABLE>
<CAPTION>
<S>                    <C>                                                                               <C>
                       2003............................................................................$  5,100
                       2004............................................................................   3,500
                       2005............................................................................   2,900
                       2006............................................................................   2,600
                       2007............................................................................   1,600
</TABLE>




7 --STOCKHOLDERS' EQUITY

     Accumulated other comprehensive loss consists of the following:

<TABLE>
<CAPTION>
                                                               FOREIGN         MARKETABLE                           ACCUMULATED
                                                               CURRENCY        SECURITIES         MINIMUM              OTHER
                                                             TRANSLATION       VALUATION          PENSION          COMPREHENSIVE
                                                              ADJUSTMENT       ADJUSTMENT        LIABILITY             LOSS
                                                              ---------        ----------        ---------          ----------
<S>                                                           <C>            <C>                <C>                 <C>
Balances, December 31, 2002..............................     $(39,200)        $  (3,463)        $  (2,123)          $ (44,786)
  Current period change..................................       17,911             1,456                 -              19,367
                                                              ---------        ---------         ---------           ---------
Balances, June 30, 2003..................................     $(21,289)        $  (2,007)        $  (2,123)          $ (25,419)
                                                              =========        =========         =========           =========
</TABLE>


     The change in the marketable securities valuation adjustment for the six
months ended June 30, 2003 includes unrealized holding gains of $1,172, ($1,864
pre-tax) on the Company's available-for-sale securities. The remaining $284
($451 pre-tax) relates to a reduction to other comprehensive loss resulting from
the investment loss discussed in Note 8.


8 -- INVESTMENT EXPENSE

     During the second quarter of 2003, the Company recorded an investment loss
of $1,018 as a result of the Company's assessment of an "other than temporary"
decline in the fair market value of an investment in certain common stock. This
amount is included in investment expense as part of total non operating
expense/(income) for the period. There were no sales of marketable equity
securities during the six months ended June 30, 2003.


9-- INCOME TAXES

     The effective income tax rate for the six months ended June 30, 2003 was a
25% tax expense, compared to a 326% tax benefit for the six months ended June
30, 2002, which reflects the Company's assessment of its annual effective income
tax rate. Factors affecting the Company's estimated annual effective income tax
rate include increased research and development expenditures in the United
States, the statutory income tax rates and mix of earnings among tax
jurisdictions, amortization of certain intangible assets and other items which
are not deductible for tax purposes, and research and experimentation tax
credits. In addition, the estimated annual effective rate for the six months
ended June 30, 2003 included the effect of estimated valuation allowances, since
the Company does not have the ability to carry back or anticipate the ability to
carry forward its United States net operating losses. The effective rate for the
six months ended June 30, 2002 included the effect of restructuring and related
charges. Accordingly, the tax benefit related to the restructuring and related
charges of approximately $6,000 was recorded in the first quarter of 2002.



                                       10
<PAGE>

10 -- ACQUISITION

     On December 31, 2002, the Company acquired the brewing and enzyme business
of Rhodia Food UK Limited for a total cash purchase price of $8,925. The
acquisition included technology, product lines and personnel. The acquisition
expanded the Company's Bioproducts portfolio and technical service capabilities
in the food, feed and specialty enzyme market sector. No facilities were
included in the transaction. The acquisition has been accounted for under the
purchase method in accordance with SFAS No. 141, "Business Combinations." The
results of operations of the acquired business were consolidated with the
Company's results of operations beginning January 1, 2003.

     According to the Company's preliminary allocation of the purchase price on
December 31, 2002, the $8,925 consists solely of intangible assets. Due to the
effect of foreign currency translation, additional acquisition costs and the
sale of certain acquired assets, the intangible assets are $8,703 at June 30,
2003. The Company is continuing to evaluate the allocation of the purchase price
for the acquisition, including the segregation of separately identifiable
intangible assets. The Company anticipates that this process will be completed
during 2003.


11 -- RESTRUCTURING AND RELATED CHARGES

     During February 2002, as a result of the acquisition of Enzyme Bio-Systems
Ltd. (EBS), now known as Genencor International Wisconsin, Inc., from Corn
Products International, Inc. and general economic conditions in Latin America,
including the devaluation of the Argentine Peso, the Company engaged in a plan
to restructure its overall supply infrastructure by ceasing operations at its
Elkhart, Indiana plant and downsizing its Argentine facilities. As a result of
the plan, restructuring and related charges of $16,379 were recorded in the
Company's operating earnings in the six months ended June 30, 2002. This
restructuring was completed during 2002.


12 -- SEGMENT REPORTING

     The Company has adopted SFAS No. 131 "Disclosures about Segments of an
Enterprise and Related Information." Segments were determined based on products
and services provided by each segment. Accounting policies for the segments are
the same as those described in Note 1, "Summary of Significant Accounting
Policies" of the Company's Annual Report on Form 10-K for the year ended
December 31, 2002. Performance of the segments is evaluated based on operating
income of the segment. No items below operating income are allocated to the
segments. The Company accounts for transactions, if any, between the segments as
though they were transactions with third parties at approximate market prices.
There were no material inter-segment transactions in the periods presented.
During the first quarter of 2003, the Company modified its managerial financial
reporting to reflect two operating segments: Bioproducts and Health Care.
Accordingly, the Company is providing data in this new financial structure for
the three months and six months ended June 30, 2003 and 2002.

     The Bioproducts segment develops and delivers products and services to the
industrial, consumer and agri-processing markets to a global customer base. All
of the Company's current product revenues are derived from this segment.

     The Health Care segment is focused on expanding the Company's current
technology and product platforms into the health care market. This segment is
primarily engaged in the performance of research and development, the securing
of intellectual property and the establishment of strategic investments and
collaborations.

     The following table provides information by business segment; information
for 2002 has been restated to reflect the reorganized business segments:

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------
FOR THE THREE MONTHS ENDED JUNE 30, 2003
------------------------------------------------------------------------------------------------------
                                                                            Corporate  Consolidated
                              Bioproducts   Health Care   Segment Subtotal  and Other     Totals
------------------------------------------------------------------------------------------------------
<S>                             <C>           <C>            <C>           <C>           <C>
Product revenue ............    $89,744       $     -        $89,744       $   -         $89,744
Fees and royalty revenues ..      6,453           150          6,603           -           6,603
Total revenues .............     96,197           150         96,347           -          96,347
Research and development ...     10,914         5,919         16,833           -          16,833
Operating income/(loss) ....     17,737        (7,536)        10,201          91          10,292
</TABLE>



                                       11
<PAGE>


<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------------
FOR THE THREE MONTHS ENDED JUNE 30, 2002
--------------------------------------------------------------------------------------------------------
                                                                              Corporate    Consolidated
                               Bioproducts   Health Care   Segment Subtotal   and Other       Totals
--------------------------------------------------------------------------------------------------------
<S>                             <C>           <C>              <C>            <C>            <C>
Product revenue ............     $85,470       $      -         $ 85,470       $      -       $ 85,470
Fees and royalty revenues ..       5,162              -            5,162              -          5,162
Total revenues .............      90,632              -           90,632              -         90,632
Research and development ...      10,282          7,028           17,310              -         17,310
Operating income/(loss) ....      18,798         (9,669)           9,129          1,965         11,094
</TABLE>

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------------
FOR THE SIX MONTHS ENDED JUNE 30, 2003
--------------------------------------------------------------------------------------------------------
                                                                              Corporate    Consolidated
                               Bioproducts   Health Care   Segment Subtotal   and Other       Totals
--------------------------------------------------------------------------------------------------------
<S>                             <C>           <C>              <C>            <C>            <C>
Product revenue ............     $179,782      $    -           $179,782       $      -       $179,782
Fees and royalty revenues ..       12,001          225            12,226              -         12,226
Total revenues .............      191,783          225           192,008              -        192,008
Research and development ...       21,234       12,059            33,293              -         33,293
Operating income/(loss) ....       36,795      (15,442)           21,353           (298)        21,055
</TABLE>

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------------
FOR THE SIX MONTHS ENDED JUNE 30, 2002
--------------------------------------------------------------------------------------------------------
                                                                              Corporate    Consolidated
                               Bioproducts   Health Care   Segment Subtotal   and Other       Totals
--------------------------------------------------------------------------------------------------------
<S>                             <C>           <C>              <C>            <C>            <C>
Product revenue ............     $161,018      $     -          $161,018       $      -       $161,018
Fees and royalty revenues ..       10,349           75            10,424              -         10,424
Total revenues .......... ..      171,367           75           171,442              -        171,442
Research and development ...       18,756       14,186            32,942              -         32,942
Operating income/(loss) ....       18,575      (19,391)             (816)         3,542          2,726
</TABLE>


<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------------
                                                   DECEMBER 31, 2002
--------------------------------------------------------------------------------------------------------
                                                                              Corporate    Consolidated
                               Bioproducts   Health Care   Segment Subtotal   and Other       Totals
--------------------------------------------------------------------------------------------------------
<S>                             <C>           <C>              <C>            <C>            <C>
Total assets ................    $467,782      $ 5,719          $473,501       $181,421       $654,922
Depreciation and amortization      31,127        2,064            33,191              -         33,191
Capital additions ...........      18,153        1,397            19,550              -         19,550
</TABLE>



                                       12
<PAGE>


     The following table provides a reconciliation of segment information to
total consolidated information:

<TABLE>
<CAPTION>
                                                                THREE MONTHS ENDED               SIX MONTHS ENDED
                                                                    JUNE 30,                        JUNE 30,
                                                                    --------                        --------
                                                           JUNE 30,        JUNE 30,         JUNE 30,        JUNE 30,
                                                            2003             2002            2003             2002
                                                            ----             ----            ----             ----
<S>                                                        <C>             <C>             <C>             <C>
Net income:
  Operating income/(loss) for reportable segments...       $ 10,201        $  9,129        $ 21,353        $   (816)
  Other (income)/expense ...........................            (91)         (1,965)            298          (3,542)
  Investment expense ...............................          1,018              --           1,018              --
  Interest expense .................................          1,569           2,044           3,589           4,564
  Interest (income) ................................         (1,558)         (1,311)         (2,403)         (2,712)
  Provision for/(benefit from) income taxes.........          1,644           5,578           4,712          (2,850)
                                                           --------        --------        --------        --------
     Consolidated net income .......................       $  7,619        $  4,783        $ 14,139        $  3,724
                                                           ========        ========        ========        ========
</TABLE>


<TABLE>
<CAPTION>
Total assets:                                                                               DECEMBER 31,
                                                                                                2002
                                                                                                ----
<S>                                                                                        <C>
   Total assets for reportable segments..............................................      $      473,501
   Cash and cash equivalents not allocated to business segments......................             163,376
   Deferred tax assets...............................................................              18,045
                                                                                           --------------
          Total consolidated assets..................................................      $      654,922
                                                                                           ==============
</TABLE>




                                       13
<PAGE>


ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        OF OPERATIONS

     The following discussion of our financial condition and results of
operations should be read in conjunction with the consolidated financial
statements and the notes to those statements included in our 2002 Annual Report
on Form 10-K and the condensed consolidated unaudited financial statements and
related notes included elsewhere in this report. In addition to disclosing
results for the three months and six months ended June 30, 2003 and 2002 that
are determined in accordance with Generally Accepted Accounting Principles
("GAAP"), the Company also discloses non-GAAP financial measures that exclude
the effects of restructuring and related charges recorded in the 2002 period on
consolidated net income available to common stockholders and diluted earnings
per share and on the operating income of its Bioproducts segment. The Company
is presenting non-GAAP financial measures excluding the effects of the
restructuring and related charges because the Company believes it is useful for
investors in assessing the Company's financial results compared to the same
period in the prior year. Within the text, in connection with each non-GAAP
financial measure presented, the Company has presented the most directly
comparable financial measure calculated in accordance with GAAP and has provided
a reconciliation of the differences between the non-GAAP financial measure with
its most directly comparable financial measure calculated and presented in
accordance with GAAP.


OVERVIEW

     We are a diversified biotechnology company that develops and delivers
products and services to the industrial, consumer, agri-processing and health
care markets. Our current revenues result primarily from the sale of enzyme
products to the cleaning, grain processing and textile industries, with the
remainder of our revenues from research funding, fees and royalties. We intend
to apply our proven and proprietary technologies and manufacturing capabilities
to expand sales in our existing markets and address new opportunities in the
health care, agri-processing, industrial, and consumer markets. We have formed,
and plan to continue to form, strategic alliances with market leaders to
collaborate with us to develop and launch products.

     We manufacture our products at our eight manufacturing facilities located
in the United States, Finland, Belgium, China and Argentina. These products are
then marketed to the industrial, consumer and agri-processing markets through
our direct sales organization and other distribution channels. For the year
ended December 31, 2002, we derived approximately 50% of our revenues from our
foreign operations. For the six months ended June 30, 2003, we derived
approximately 55% of our revenues from foreign operations.


SUMMARY OF RESULTS

     For the three months ended June 30, 2003, we reported net income available
to common stockholders of $5.8 million, or $0.10 per diluted share, compared to
net income available to common stockholders of $3.0 million, or $0.05 per
diluted share for the three months ended June 30, 2002. For the six months ended
June 30, 2003, net income available for common stockholders was $10.5 million,
or $0.18 per diluted share, compared to approximately breakeven, for the six
months ended June 30, 2002. During the six months ended June 30, 2002, we
recorded restructuring and related charges of $16.4 million, or $10.3 million on
an after-tax basis. Before these charges, we would have reported net income
available to common stockholders of $10.5 million, or $0.17 per diluted share
for the six months ended June 30, 2002.


RESULTS OF OPERATIONS

Comparison of the Three Months Ended June 30, 2003 and 2002

     Revenues. Total revenues for the three-month period ended June 30, 2003
increased $5.7 million, or 6%, to $96.3 million from the three-month period
ended June 30, 2002, due to increases in product revenues and fees and royalty
revenues.

     Product Revenues. Product revenues for the three months ended June 30, 2003
increased $4.2 million, or 5%, to $89.7 million from the three months ended June
30, 2002. For the three months ended June 30, 2003, unit volume/mix increased 2%
and the impact of foreign currency increased revenues 8% while average prices
fell 5%. Volume/mix increased primarily in our food, feed and specialties
markets, partially offset by a decrease in our grain processing markets.



                                       14
<PAGE>

     Regionally, North American product revenues for the three months ended June
30, 2003 decreased $2.8 million, or 7%, to $39.1 million from the three months
ended June 30, 2002, driven primarily by decreased sales to our cleaning and
fabric care and grain processing markets, partially offset by increased sales to
our food, feed and specialties markets. Product revenues in Europe, Africa and
the Middle East for the three months ended June 30, 2003 increased $7.5 million,
or 27%, to $35.8 million from the three months ended June 30, 2002, driven
primarily by increased sales to our food, feed and specialties markets and
cleaning and fabric care markets. Our product revenues in the Asia Pacific
region decreased $0.2 million, or 2%, to $11.3 million for three months ended
June 30, 2003 from the three months ended June 30, 2002 due primarily to
decreased sales to our grain processing markets. Our product revenues in Latin
America for the three months ended June 30, 2003 decreased $0.3 million, or 8%,
to $3.5 million from the three months ended June 30, 2002, primarily due to
decreased sales to our cleaning and fabric care markets, partially offset by
increased sales to our grain processing markets.

     Fees and Royalty Revenues. Fees and royalty revenues increased $1.4
million, or 27%, to $6.6 million, for the three months ended June 30, 2003 from
the three months ended June 30, 2002, due to increases in government and
customer funded research.

     Funded research revenues for the three months ended June 30, 2003 increased
$1.1 million, or 22%, to $6.1 million from the three months ended June 30, 2002.
Revenues generated by research funding result from collaborative agreements with
various parties, including the U.S. Government, whereby we perform research
activities and receive revenues that partially reimburse us for expenses
incurred. Under such agreements, we retain a proprietary interest in the
products and technology developed.

     Our funded research revenue as it relates to U.S. Government collaborations
increased $0.8 million, or 89%, to $1.7 million for the three months ended June
30, 2003 from the three months ended June 30, 2002 primarily due to funding
provided by the National Renewable Energy Laboratory to develop an enzymatic
process to convert biomass into bioethanol. Funded research revenues provided by
customers increased $0.3 million, or 7%, to $4.4 million for the three months
ended June 30, 2003 from the three months ended June 30, 2002, primarily driven
by funding from our strategic alliance with the Dow Corning Corporation.

     Royalties increased $0.2 million to $0.4 million for the three months ended
June 30, 2003 from the three months ended June 30, 2002, due primarily to the
timing of customer royalty payments that are based on the sales of the
customers' products produced using our technology. License fees were $0.1
million for the three months ended June 30, 2003. There were no such fees for
the three months ended June 30, 2002.

Operating Expenses

     Cost of Products Sold. Cost of products sold increased $5.7 million, or
12%, to $51.8 million for the three months ended June 30, 2003 from the three
months ended June 30, 2002. Our expanded sales volume/mix increased costs $3.2
million, along with increases due to the impact of the U.S. Dollar against
foreign currencies, primarily the Euro, of $4.5 million. These increases were
partially offset by a decrease of $2.0 million due to the sale of lower cost
inventories.

     Gross Profit and Margins from Products Sold. Gross profit from products
sold decreased $1.5 million, or 4%, to $37.9 million for the three months ended
June 30, 2003 from the three months ended June 30, 2002 and gross margin
decreased to 42.3% for the three months ended June 30, 2003 from 46.1% for the
three months ended June 30, 2002. The overall decrease was primarily driven by a
decline in average selling prices. Also, while our gross profit benefited by
$2.1 million due to the impact of the U.S. Dollar against foreign currencies,
primarily the Euro, this resulted in a 1% decline in gross margin.

     Research and Development. Research and development expenses primarily
consist of the personnel-related, consulting, and facilities costs incurred in
connection with our research activities conducted in Palo Alto, California and
Leiden, the Netherlands. These expenses decreased $0.5 million, or 3%, to $16.8
million for the three months ended June 30, 2003 from the three months ended
June 30, 2002, due primarily to decreases in outside services of $1.3 million
and supply costs of $0.5 million, partially offset by an increase in
personnel-related costs, including salaries, benefits and travel expenses and
other costs of $1.2 million. As a part of total research and development
expenses, estimated expenses related to research collaborations partially funded
by customers decreased $0.7 million, or 18%, to $3.1 million for the three
months ended June 30, 2003 from the three months ended June 30, 2002.


                                       15
<PAGE>

     Sales, Marketing and Business Development. Sales, marketing and business
development expenses primarily consist of the personnel-related and marketing
costs incurred by our global sales force. These expenses decreased $0.7 million,
or 8%, to $7.9 million for the three months ended June 30, 2003 from the three
months ended June 30, 2002, due primarily to decreases in outside services of
$0.8 million and incentive compensation of $0.2 million, partially offset by an
increase in personnel-related costs, including salaries, benefits, commissions
and travel expenses of $0.5 million.

     General and Administrative. General and administrative expenses include the
costs of our corporate executive, finance, information technology, legal, human
resources, and communications functions. In total, these expenses decreased $0.3
million, or 4%, to $8.0 million for the three months ended June 30, 2003 from
the three months ended June 30, 2002, due primarily to decreases in outside
services of $0.9 million and advertising and promotions of $0.2 million,
partially offset by an increase in personnel-related costs, including salaries,
benefits, travel expenses and incentive compensation of $0.8 million.

     Amortization of Intangible Assets. We amortize our definite-lived
intangible assets, consisting of patents, licenses, customer lists and other
contractual agreements on a straight-line basis over their estimated useful
lives. Amortization expense increased $0.2 million, or 15%, to $1.5 million for
the three months ended June 30, 2003 from the three months ended June 30, 2002
primarily due to additional amortization of newly acquired intangible assets.

     Other Expense and Income. Other expense and income relates primarily to
foreign currency exchange gains and losses on transactions denominated in other
than the functional currency of the entity in which the transaction occurred.
Other expense for the three months ended June 30, 2003 was $0.1 million as
compared with other income of $2.1 million for the three months ended June 30,
2002. This $2.2 million decrease in income was due mainly to Argentine Peso and
Euro-driven foreign currency transaction gains during the three months ended
June 30, 2002.

     Deferred Compensation. We measure deferred compensation for options
granted to employees as the difference between the grant price and the fair
value of our common stock on the date we granted the options.

     On June 6, 2003, we granted 0.05 million shares of restricted common stock
to certain executive officers. These restricted shares were granted at fair
market value at the date of grant and the restrictions on these awards expire
three years from the date of grant. Deferred compensation expense of $0.7
million was recorded in connection with these awards and was determined based on
the number of granted restricted shares and the fair market value on the grant
date. This amount was recorded as a component of stockholders' equity and will
be amortized as a charge to operations over the vesting period of the awards.

     Amortization of deferred stock-based compensation expense was $0.2 million
and $0.7 million for the three months ended June 30, 2003 and 2002,
respectively, and was reported in our Consolidated Statements of Operations as
follows (in millions):

<TABLE>
<CAPTION>
                                                                                      2003                 2002
                                                                                      ----                 ----
<S>                                                                            <C>                  <C>
Cost of products sold......................................................     $         -          $         -
Research and development...................................................             0.1                  0.2
Sales, marketing and business development..................................               -                  0.3
General and administrative.................................................             0.1                  0.2
                                                                                -----------          -----------
Total amortization of deferred compensation expense                             $       0.2          $       0.7
                                                                                ===========          ===========
</TABLE>


Non Operating Expense and Income

     Investment Expense. We recorded an investment loss of $1.0 million in the
three months ended June 30, 2003, as a result of our assessment of an "other
than temporary" decline in the fair market value of an investment in certain
common stock. There was no such investment income or loss in the three months
ended June 30, 2002.

     Interest Income. Interest income increased $0.3 million, or 23%, to $1.6
million for the three months ended June 30, 2003 from the three months ended
June 30, 2002, due primarily to interest received on the settlement of a tax
refund claim, partially offset by a reduction in interest received due to our
lower cash balances, as discussed under the heading "Liquidity and Capital
Resources."


                                       16
<PAGE>


      Income Taxes. The effective income tax rate for the three months ended
June 30, 2003 was an 18% tax expense, compared to a 54% tax expense for the
three months ended June 30, 2002, which reflects our assessment of the annual
effective income tax rate. Factors affecting our estimated annual effective
income tax rate include increased research and development expenditures in the
United States, the statutory income tax rates and mix of earnings among tax
jurisdictions, amortization of certain intangible assets and other items which
are not deductible for tax purposes, and research and experimentation tax
credits. In addition, the estimated annual effective rate in the three months
ended June 30, 2003 included the effect of estimated valuation allowances, since
we do not have the ability to carry back or anticipate the ability to carry
forward our United States net operating losses.


Comparison of the Six Months Ended June 30, 2003 and 2002

     Revenues. Total revenues for the six months ended June 30, 2003 increased
$20.6 million, or 12%, to $192.0 million from the six months ended June 30,
2002, due to increases in both product revenues and fees and royalty revenues.

     Product Revenues. Product revenues in the six months ended June 30, 2003
increased $18.8 million, or 12%, to $179.8 million from the six months ended
June 30, 2002. For the six months ended June 30, 2003, unit volume/mix grew 8%
along with increased currency impact of 8%, while average prices fell 4%.
Volume/mix increased in our grain processing, cleaning and fabric care and food,
feed, and specialties markets.

     Regionally, North American product revenues for the six months ended June
30, 2003 decreased $1.2 million, or 2%, to $76.8 million from the six months
ended June 30, 2002, driven primarily by a decrease in sales to our cleaning and
fabric care markets, partially offset by an increase in sales to our food,
feed and specialties and grain processing markets. Product revenues in Europe,
Africa and the Middle East for the six months ended June 30, 2003 increased
$15.7 million, or 28%, to $71.8 million from the six months ended June 30, 2002,
driven primarily by increased sales to our food, feed and specialties markets,
grain processing and cleaning and fabric care markets including protease enzymes
sales to a major customer. Our product revenues in Latin America for the six
months ended June 30, 2003 increased $0.3 million, or 5%, to $6.8 million from
the six months ended June 30, 2002 due primarily to increased sales to our grain
processing and food, feed and specialties markets, partially offset by decreased
sales to our cleaning and fabric care markets. Product revenues in the Asia
Pacific region increased $4.0 million, or 20%, to $24.4 million for the six
months ended June 30, 2003 from the six months ended June 30, 2002, due mainly
to increased sales to our food, feed and specialties, grain processing and
cleaning and fabric care markets.

     Fees and Royalty Revenues. Fees and royalty revenues increased $1.8
million, or 17%, to $12.2 million for the six months ended June 30, 2003 from
the six months ended June 30, 2002, due primarily to an increase in government
and customer funded research revenues.

     Funded research revenues increased $1.4 million, or 14%, to $11.2 million
for the six months ended June 30, 2003 from the six months ended June 30, 2002.
Revenues generated by research funding result from collaborative agreements with
various parties, including the U.S. Government, whereby we perform research
activities and receive revenues that partially reimburse us for expenses
incurred. Under such agreements, we retain a proprietary interest in the
products and technology developed. Our funded research revenue as it relates to
U.S. Government collaborations increased $0.9 million, or 47%, to $2.8 million
for the six months ended June 30, 2003 from the six months ended June 30, 2002,
primarily due to funding provided by the National Renewable Energy Laboratory to
develop an enzymatic process to convert biomass into bioethanol. Funded research
revenues provided by customers increased $0.5 million, or 6%, to $8.4 million
for the six months ended June 30, 2003 from the six months ended June 30, 2002,
primarily driven by funding from our strategic alliance with the Dow Corning
Corporation.

     Royalties increased $0.4 million, or 80%, to $0.9 million for the six
months ended June 30, 2003 from the six months ended June 30, 2002, due
primarily to the timing of customer royalty payments that are based on the sales
of the customers' products produced using our technology. License fees increased
$0.1 million to $0.2 million for the six months ended June 30, 2003 from the six
months ended June 30, 2002.

Operating Expenses

     Cost of Products Sold. Cost of products sold increased $14.4 million, or
16%, to $102.6 million for the six months ended June 30, 2003 from the six
months ended June 30, 2002. Our expanded sales volume/mix increased costs $8.2



                                       17
<PAGE>

million, along with increases of $7.4 million due to the impact of the U.S.
Dollar against foreign currencies, primarily the Euro. These increases were
partially offset by a $1.2 million decrease due to the sale of lower cost
inventories.

     Gross Profit and Margins from Products Sold. Gross profit from products
sold increased $4.4 million, or 6%, to $77.2 million for the six months ended
June 30, 2003 from the six months ended June 30, 2002. This overall increase was
caused by significant product revenue related factors including an 8% increase
in volume/mix processed through our plants, partially offset by an average price
decline of 4%. This net increase in gross profit was also driven by a $5.1
million increase due to the impact of the U.S. Dollar against foreign
currencies, primarily the Euro. As a result of these factors however, gross
margin on product revenue decreased to 42.9% for the six months ended June 30,
2003 from 45.2% for the six months ended June 30, 2002, primarily driven by
price reductions.

     Research and Development. Research and development expenses increased $0.4
million, or 1%, to $33.3 million for the six months ended June 30, 2003 from the
six months ended June 30, 2002, primarily due to increases in personnel-related
costs, including salaries, benefits and travel expenses of $2.8 million,
partially offset by decreases in outside services of $2.1 million and supply
costs. As a part of total research and development expenses, estimated expenses
related to research collaborations partially funded by customers decreased $1.5
million, or 20%, to $6.2 million for the six months ended June 30, 2003 from the
six months ended June 30, 2002.

     Sales, Marketing and Business Development. Sales, marketing and business
development expenses decreased $0.1 million, or 1%, to $15.6 million for the six
months ended June 30, 2003 from the six months ended June 30, 2002, primarily
due to decreases in incentive compensation of $0.5 million and outside services
of $0.4 million, partially offset by an increase in personnel-related costs,
including salaries, benefits, commissions and travel expenses of $0.7 million.

     General and Administrative. General and administrative expenses decreased
$0.5 million, or 3%, to $15.8 million for the six months ended June 30, 2003
from the six months ended June 30, 2002, due primarily to decreases in outside
services of $1.6 million and advertising and promotion of $0.4 million,
partially offset by an increase in personnel-related costs, including salaries,
benefits, and travel expenses of $1.6 million.

     Amortization of Intangible Assets. Amortization expense increased $0.3
million, or 12%, to $2.9 million for the six months ended June 30, 2003 from the
six months ended June 30, 2002, primarily due to additional amortization of
newly acquired intangible assets.

     Other Expense and Income. Other expense for the six months ended June 30,
2003 was $0.8 million as compared to $3.5 million of other income for the six
months ended June 30, 2002. This difference in income of $4.3 million was
primarily due to Argentine Peso and Euro-driven foreign currency transaction
gains during the six months ended June 30, 2002.

     Deferred Compensation. We measure deferred compensation for options
granted to employees as the difference between the grant price and the fair
value of our common stock on the date we granted the options.

     On June 6, 2003, we granted 0.05 million shares of restricted common stock
to certain executive officers. These restricted shares were granted at fair
market value at the date of grant and the restrictions on these awards expire
three years from the date of grant. Deferred compensation expense of $0.7
million was recorded in connection with these awards and was determined based on
the number of granted restricted shares and the fair market value on the grant
date. This amount was recorded as a component of stockholders' equity and will
be amortized as a charge to operations over the vesting period of the awards.

     Amortization of deferred stock-based compensation expense was $0.6 million
and $1.6 million for the six months ended June 30, 2003 and 2002, respectively,
and was reported in our Consolidated Statements of Operations as follows (in
millions):

<TABLE>
<CAPTION>
                                                                                      2003                 2002
                                                                                      ----                 ----
<S>                                                                             <C>                  <C>
Cost of products sold......................................................     $         -          $       0.2
Research and development...................................................             0.3                  0.3
Sales, marketing and business development..................................               -                  0.7
General and administrative.................................................             0.3                  0.4
                                                                                -----------          -----------
Total amortization of deferred compensation expense                             $       0.6          $       1.6
                                                                                ===========          ===========
</TABLE>



                                       18
<PAGE>


Non Operating Expense and Income

     Investment Expense. We recorded an investment loss of $1.0 million in the
six months ended June 30, 2003, as a result of our assessment of an "other than
temporary" decline in the fair market value of an investment in certain common
stock. There was no such investment income or loss in the six months ended June
30, 2002

     Interest Income. Interest income decreased $0.3 million, or 11%, to $2.4
million for the six months ended June 30, 2003 from the six months ended June
30, 2002 due mainly to the reduction of interest received due to our lower cash
balances, discussed below under the heading "Liquidity and Capital Resources."

     Income Taxes. The effective income tax rate for the six months ended June
30, 2003 was a 25% tax expense, compared to a 326% tax benefit for the six
months ended June 30, 2002, which reflects our assessment of the annual
effective income tax rate. Factors affecting our estimated annual effective
income tax rate include increased research and development expenditures in the
United States, the statutory income tax rates and mix of earnings among tax
jurisdictions, amortization of certain intangible assets and other items which
are not deductible for tax purposes, and research and experimentation tax
credits. In addition, the estimated annual effective rate for the six months
ended June 30, 2003 included the effect of estimated valuation allowances, since
we do not have the ability to carry back or anticipate the ability to carry
forward our United States net operating losses. The effective rate for the six
months ended June 30, 2002 included the effect of restructuring and related
charges. Accordingly, the tax benefit related to the restructuring and related
charges of approximately $6.0 million was recorded in the first quarter of 2002.


FINANCIAL RESULTS BY SEGMENT

     During the three months ended March 31, 2003, we modified our managerial
financial reporting to provide information that aligns with the two-segment
structure of Bioproducts and Health Care. Accordingly, we provided historical
financial data in this new financial segment-reporting format for the three
months and the six months ended June 30, 2003 and 2002.

     The Bioproducts segment develops and delivers products and services for the
industrial, consumer and agri-processing markets to a global customer base. All
of our current product revenues are derived from this segment. For the three
months ended June 30, 2003, the Bioproducts segment achieved operating income of
$17.7 million as compared to an operating income of $18.8 million for the three
months ended June 30, 2002. For the six months ended June 30, 2003, the
Bioproducts segment achieved operating income of $36.8 million as compared to an
operating income of $18.6 million for the six months ended June 30, 2002. For
the six months ended June 30, 2002, Bioproducts recorded restructuring and
related costs of $16.4 million. Before these restructuring and related charges,
the segment would have reported operating income of $35.0 million for the three
months ended June 30, 2002.

     The Health Care segment is focused on expanding our current technology and
product platforms into the health care market. This segment is primarily engaged
in the performance of research and development, the securing of intellectual
property and the establishment of strategic investments and collaborations. For
the three months ended June 30, 2003, the Health Care segment experienced an
operating loss of $7.5 million as compared to an operating loss of $9.7 million
for the three months ended June 30, 2002. For the six months ended June 30,
2003, the Health Care segment experienced an operating loss of $15.4 million as
compared to an operating loss of $19.4 million for the six months ended June 30,
2002.


ACQUISITION

     On December 31, 2002, we acquired the brewing and enzyme business of Rhodia
Food UK Limited for a total cash purchase price of $8.9 million. The acquisition
included technology, product lines and personnel. The acquisition expanded our
Bioproducts portfolio and technical service capabilities in the food, feed and
specialty enzyme market sector. No facilities were included in the transaction.
The acquisition has been accounted for under the purchase method in accordance
with SFAS No. 141, "Business Combinations." The results of operations of the
acquired business were consolidated with our results of operations beginning
January 1, 2003.

     According to our preliminary allocation of the purchase price on December
31, 2002, the $8.9 million consists solely of intangible assets. Due to the
effect of foreign currency translation, additional acquisition costs and the
sale of certain acquired assets, the intangible assets are $8.7 million at June
30, 2003. We are continuing to evaluate the allocation of the



                                       19
<PAGE>


purchase price for the acquisition, including the segregation of separately
identifiable intangible assets. We anticipate that this process will be
completed during 2003.


RESTRUCTURING AND RELATED CHARGES

     During February 2002, as a result of the acquisition of EBS and general
economic conditions in Latin America, including the devaluation of the Argentine
Peso, we engaged in a plan to restructure our overall supply infrastructure by
ceasing operations at our Elkhart, Indiana plant and downsizing our Argentine
facilities. As a result of the plan, restructuring and related charges of $16.4
million were recorded in our operating earnings for the six months ended June
30, 2002. This restructuring was completed during 2002.


WAREHOUSE INVENTORY LOSS

     During the quarter ended June 30, 2003, we sustained damage to our finished
bioproduct inventory as a result of an accident in a third party warehouse in
Rotterdam, the Netherlands. While there has been no material interruption in
product flow to our customers, we reduced our inventories by approximately $7.5
million to reflect the estimated amount of product that was lost. In addition,
approximately $1.0 million of other costs were incurred as a result of the
accident. These amounts have been recorded in other current assets as a
receivable from our insurer. Certain reduced profits and additional costs, such
as production inefficiencies, additional freight and use of overtime are
reflected in the results of operations during the second quarter ended June 30,
2003. While we believe that these reduced profits and additional costs will be
subject to insurance recovery, we are unable to estimate the ultimate recovery
at this time.


LIQUIDITY AND CAPITAL RESOURCES

     Our funding needs consist primarily of capital expenditures, research and
development activities, sales and marketing expenses, and general corporate
purposes. We have financed our operations primarily through cash from the sale
of products, the sale of stock, research and development funding from partners,
government grants, and short-term and long-term borrowings.

     We believe that our current cash and cash equivalent balances plus funds to
be provided from our current year operating activities, together with those
available under our lines of credit, will satisfy our funding needs over the
next twelve months. Factors that could negatively impact our cash position
include, but are not limited to, future levels of product revenues, fees and
royalty revenues, expense levels, capital expenditures, acquisitions, and
foreign currency exchange rate fluctuations.

     As of June 30, 2003, cash and cash equivalents totaled $155.4 million. The
funds were invested in short-term instruments, including A-1/P1 and A-2/P2 rated
commercial paper, AAA and AA rated medium term notes, institutional money market
funds, auction rate preferred securities and bank deposits.

     Cash provided by operations was $15.9 million and $10.2 million for the six
months ended June 30, 2003 and 2002, respectively. The increase of $5.7 million
in 2003 from 2002 was generated principally by operating income, net of non-cash
items such as depreciation and amortization, and changes in operating assets and
liabilities.

     Cash used in investing activities was $9.4 million and $44.8 million for
the six months ended June 30, 2003 and 2002, respectively. This decrease of
$35.4 million was driven primarily by the EBS acquisition of $35.8 million and
the equity investment in Seattle Genetics, Inc. of $3.0 million during the six
months ended June 30, 2002. Cash used in investing activities for the six months
ended June 30, 2003 included $1.1 million in proceeds from the sale of certain
acquired assets as discussed above in Acquisitions. Capital expenditures for the
six months ended June 30, 2003 were $10.6 million in 2003 compared with $5.9
million in 2002. A significant portion of the capital spending included process
improvement projects at our manufacturing and research and development
facilities and information technology enhancements. We also continued our
construction of a facility for the clinical-scale manufacture of human
therapeutic proteins in Rochester, New York during the six months ended June 30,
2003.

     Cash used in financing activities was $25.4 million and $27.0 million for
the six months ended June 30, 2003 and 2002, respectively. This decrease of $1.6
million was primarily driven by proceeds received from the exercise of stock
options


                                       20
<PAGE>


during the six months ended June 30, 2003. While we are permitted to pay
dividends to our common stockholders, we currently intend to utilize our
resources to finance the expansion of our business. Any future determination to
pay cash dividends to our common stockholders will be at the discretion of our
board of directors and will depend upon our financial condition, results of
operations, capital requirements, general business conditions and other factors
that the board of directors may deem relevant, including covenants in our debt
instruments that may limit our ability to declare and pay cash dividends on our
capital stock. Covenants in our senior note agreement restrict the payment of
dividends or other distributions in cash or other property to the extent the
payment puts us in default of these covenants. Such covenants include, but are
not limited to, maintaining a debt to total capitalization of no greater than
55% and a maximum ratio of debt to earnings before interest, taxes, depreciation
and amortization (EBITDA) of 3.5:1.

     At June 30, 2003, we had a $40.0 million revolving credit facility with a
syndicate of banks, which is available for general corporate purposes. The
facility, which consists of a credit agreement, makes available to the Company
$40.0 million of committed borrowings, which expires on January 31, 2004. The
facility carries fees of 0.35% on the amount of unborrowed principal under the
agreement. As of June 30, 2003, there were no borrowings under the facility.

     Our long-term debt consists primarily of the 6.82% senior notes issued in
1996 to certain institutional investors. The remaining principal amount of these
notes is $84.0 million. Annual installment payments of $28.0 million commenced
on March 30, 2002. We are currently in compliance with the financial covenants
included in the senior note agreement.

NEW ACCOUNTING PRONOUNCEMENTS

     In April 2003, the Financial Accounting Standards Board (FASB) issued
Statement of Financial Accounting Standards (SFAS) No. 149, "Amendment of
Statement 133 on Derivative Instruments and Hedging Activities." This Statement
amends SFAS No. 133 for decisions made (1) as part of the Derivatives
Implementation Group process that effectively required amendments to SFAS No.
133, (2) in connection with other FASB projects dealing with financial
instruments, and (3) in connection with implementation issues raised in relation
to the application of the definition of a derivative. This Statement is
effective for contracts entered into or modified after June 30, 2003 and for
hedging relationships designated after June 30, 2003. All provisions of this
Statement are to be applied prospectively. We will apply the provisions of this
statement as of July 1, 2003. The adoption of SFAS No. 149 will not have a
material impact on our financial position or results of operations.

     In May 2003, the FASB issued SFAS No. 150, "Accounting for Certain
Financial Instruments with Characteristics of both Liabilities and Equity." This
statement establishes standards for how we classify and measure certain
financial instruments with characteristics of both liabilities and equity. It
requires that we classify a financial instrument within its scope as a
liability. Some of the provisions of this Statement are consistent with the
current definition of liabilities in FASB Concepts Statement No. 6, "Elements of
Financial Statements." The remaining provisions of this Statement are consistent
with the FASB's proposal to revise that definition to encompass certain
obligations that a reporting entity can or must settle by issuing its own equity
shares, depending on the nature of the relationship established between the
holder and the issuer. This Statement is effective for financial instruments
entered into or modified after May 31, 2003 and otherwise is effective at the
beginning of the first interim period beginning after June 15, 2003. We are
currently assessing the impact of this new standard on our financial statements.


MARKET RISK

      Foreign currency risk and interest rate risk are the primary sources of
our market risk. Foreign operations, mainly denominated in Euros, accounted for
approximately 55% of our revenues for the six months ended June 30, 2003. We
believe that we mitigate this risk by locating our manufacturing facilities so
that the costs are denominated in the same currency as our product revenues. We
may manage the foreign currency exposures that remain through the use of foreign
currency forward contracts, currency options and off-setting currency positions
in assets and liabilities where deemed appropriate. We do not use these
instruments for speculative purposes. There were no material foreign currency
gains in connection with these types of contracts recorded in the statement of
operations for the six months ended June 30, 2003.

       As of June 30, 2003, cash and cash equivalents totaled $155.4 million. Of
this amount, $64.4 million was denominated in Euros. The remainder, or $91.0
million, was primarily denominated in U.S. Dollars. Short-term debt was mainly
comprised of our third installment of $28.0 million due March 30, 2004 under our
6.82% senior notes discussed under the heading "Liquidity and Capital Resources"
in this Report and $8.0 million of short-term debt held by our Chinese
affiliate.



                                       21
<PAGE>


We expect to refinance all of the debt held by our Chinese affiliate. To the
extent U.S. Dollar and Euro interest rates fluctuate either up or down, the
return on the cash investments will also fluctuate. To the extent such Euro cash
investments remain outstanding, we will be subject to the risks of future
foreign exchange fluctuations and the impact on the translation of these cash
investments into U.S. Dollars.

Interest Rates

     Our interest income is sensitive to changes in the general level of
short-term interest rates primarily in the United States and Europe. In this
regard, changes in the U.S. Dollar and Euro currency rates affect the interest
earned on our cash equivalents, short-term investments, and long-term
investments. Our interest expense is generated primarily from fixed rate debt.
The $84.0 million 6.82% senior notes outstanding at June 30, 2003 mature evenly
in installments of $28.0 million per year. Annual installment payments commenced
March 30, 2002.

Foreign Currency Exposure

       We conduct business throughout the world. During the six month period
ended June 30, 2003, we derived approximately 55% of our revenues from foreign
operations, and these foreign operations generated income that offset net losses
in U.S. operations during the same six month period. Economic conditions in
countries where we conduct business and changing foreign currency exchange rates
affect our financial position and results of operations. We are exposed to
changes in exchange rates in Europe, Latin America, and Asia. The Euro and
Argentine Peso present our most significant foreign currency exposure risk.
Changes in foreign currency exchange rates, especially the strengthening of the
U.S. Dollar, may have an adverse effect on our financial position and results of
operations as they are expressed in U.S. Dollars. Our manufacturing and
administrative operations for Latin America are located in Argentina. A
significant part of our Latin American revenues are denominated in U.S. Dollars.
Net foreign exchange losses from US Dollar/Euro and US Dollar/ Argentine Peso
transactions were $0.4 million for the six months ended June 30, 2003.

     Management monitors foreign currency exposures and may in the ordinary
course of business enter into foreign currency forward contracts or options
contracts related to specific foreign currency transactions or anticipated cash
flows. These contracts generally cover periods of nine months or less and are
not material. We recorded a gain of $0.1 million in the statement of operations
for the six months ended June 30, 2003 from foreign currency contracts. We do
not hedge the translation of financial statements of consolidated subsidiaries
that maintain their local books and records in foreign currencies.


RISK FACTORS

     If any of the following risks actually occur, they could harm our business,
financial condition, and/or results of operations.

IF WE FAIL TO DEVELOP PRODUCTS FOR THE HEALTH CARE AND BIOPRODUCTS MARKETS WE
ARE TARGETING, THEN WE MAY NEVER ACHIEVE A RETURN ON OUR RESEARCH AND
DEVELOPMENT EXPENDITURES OR REALIZE PRODUCT REVENUES FROM THESE MARKETS.

     A key element of our business strategy is to utilize our technologies for
the development and delivery of new products to the Health Care market and new
segments of the Bioproducts market. We intend to significantly increase our
investment in research and development to develop products for these markets.
The successful development of products is highly uncertain and is dependent on
numerous factors, many of which are beyond our control, and may include the
following:

-     The product may be ineffective or have undesirable side effects in
      preliminary and commercial testing or, specifically in the Health Care
      area, in preclinical and clinical trials;

-     The product may fail to receive necessary governmental and regulatory
      approvals, or the government may delay regulatory approvals significantly;

-     The product may not be economically viable because of manufacturing costs
      or other factors;

-     The product may not gain acceptance in the marketplace; or


                                       22
<PAGE>



-     The proprietary rights of others or competing products or technologies for
      the same application may preclude us from commercializing the product.

-     Due to these factors we may never achieve a return on our research and
      development expenditures or realize product revenues from the Health Care
      and new Bioproducts markets that we are targeting.

IF WE FAIL TO ENTER INTO STRATEGIC ALLIANCES WITH PARTNERS IN OUR TARGET MARKETS
OR INDEPENDENTLY RAISE ADDITIONAL CAPITAL, WE WILL NOT HAVE THE RESOURCES
NECESSARY TO CAPITALIZE ON ALL OF THE MARKET OPPORTUNITIES AVAILABLE TO US.

     We do not currently possess the resources necessary to independently
develop and commercialize products for all of the market opportunities that may
result from our technologies. We intend to form strategic alliances with
industry leaders in our target markets to gain access to funding for research
and development, expertise in areas we lack and distribution channels. We may
fail to enter into the necessary strategic alliances or fail to commercialize
the products anticipated from the alliances. Our alliances could be harmed if:

-     We fail to meet our agreed upon research and development objectives;

-     We disagree with our strategic partners over material terms of the
      alliances, such as intellectual property or manufacturing rights; or

-     Our strategic partners become competitors or enter into agreements with
      our competitors.

     New strategic alliances that we enter into, if any, may conflict with the
business objectives of our current strategic partners and negatively impact
existing relationships. In addition, to capitalize on the market opportunities
we have identified, we may need to seek additional capital, either through
private or public offerings of debt or equity securities. Due to market and
other conditions beyond our control, we may not be able to raise additional
capital on acceptable terms or conditions, if at all.

IF THE DEMAND FOR PROTEIN DEGRADING ENZYMES DECREASES OR IF MAJOR CUSTOMERS
REDUCE OR TERMINATE BUSINESS WITH US, OUR REVENUES COULD SIGNIFICANTLY DECLINE.

     Our largest selling family of products, protein degrading enzymes, or
proteases, accounted for approximately 52% of our 2002 revenue. If the demand
for proteases decreases or alternative proteases render our products
noncompetitive, our revenues could significantly decline.

     In addition, our five largest customers collectively accounted for over 51%
of our 2002 product revenues, with our largest customer, The Procter & Gamble
Company, accounting for over 35% of such revenues. Our five largest customers in
2002 were Benckiser N.V., Cargill, Incorporated, Danisco Animal Nutrition - the
feed ingredients business unit of Danisco A/S which was formerly known as
Finnfeeds, The Procter & Gamble Company, and Unilever N.V. Any one of these
customers may reduce their level of business with us. Should any of our largest
customers decide to reduce or terminate business with us, our revenues and
profitability could decline significantly.

     We have arrangements of various durations with our major customers and are
routinely involved in discussions regarding the status of these relationships.
These discussions may lead to extensions or new commercial arrangements, or may
be unsuccessful. Our customer relationships involve uncertainty by virtue of
economic conditions, customer needs, competitive pressures, our production
capabilities and other factors. Consequently, our customer base will change over
time as will the nature of our relationships with individual customers,
including major customers. For example, we currently expect that our business
with Corn Products International, Inc., combined with decreased volume with
Unilever N.V., may cause Corn Products to qualify as one of our five largest
customers for 2003.

WE INTEND TO ACQUIRE BUSINESSES, TECHNOLOGIES AND PRODUCTS, BUT WE MAY FAIL TO
REALIZE THE ANTICIPATED BENEFITS OF SUCH ACQUISITIONS AND WE MAY INCUR COSTS
THAT COULD SIGNIFICANTLY NEGATIVELY IMPACT OUR PROFITABILITY.

     In the future, we may acquire other businesses, technologies and products
that we believe are a strategic fit with our business. If we undertake any
transaction of this sort, we may not be able to successfully integrate any
businesses, products, technologies or personnel that we might acquire without a
significant expenditure of operating, financial and management resources, if at
all. Further, we may fail to realize the anticipated benefits of any
acquisition. Future acquisitions could dilute



                                       23
<PAGE>


our stockholders' interest in us and could cause us to incur substantial debt,
expose us to contingent liabilities and could negatively impact our
profitability.

IF WE FAIL TO SECURE ADEQUATE INTELLECTUAL PROPERTY PROTECTION OR BECOME
INVOLVED IN AN INTELLECTUAL PROPERTY DISPUTE, IT COULD SIGNIFICANTLY HARM OUR
FINANCIAL RESULTS AND ABILITY TO COMPETE.

     The patent positions of biotechnology companies, including our patent
positions, can be highly uncertain and involve complex legal and factual
questions, and, therefore, enforceability is uncertain. We will be able to
protect our proprietary rights from unauthorized use by third parties only to
the extent that we protect our technologies with valid and enforceable patents
or as trade secrets. We rely in part on trade secret protection for our
confidential and proprietary information by entering into confidentiality
agreements and non-disclosure policies with our employees and consultants.
Nonetheless, confidential and proprietary information may be disclosed, and
others may independently develop substantially equivalent information and
techniques or otherwise gain access to our trade secrets.

     We file patent applications in the United States and in foreign countries
as part of our strategy to protect our proprietary products and technologies.
The loss of significant patents or the failure of patents to issue from pending
patent applications that we consider significant could impair our operations. In
addition, third parties could successfully challenge, invalidate or circumvent
our issued patents or patents licensed to us so that our patent rights would not
create an effective competitive barrier. Further, we may not obtain the patents
or licenses to technologies that we will need to develop products for our target
markets. The laws of some foreign countries may also not protect our
intellectual property rights to the same extent as United States law.

     Extensive litigation regarding patents and other intellectual property
rights is common in the biotechnology industry. In the ordinary course of
business, we periodically receive notices of potential infringement of patents
held by others and patent applications that may mature to patents held by
others. The impact of such claims of potential infringement, as may from time to
time become known to us, are difficult to assess. In the event of an
intellectual property dispute, we may become involved in litigation.
Intellectual property litigation can be expensive and may divert management's
time and resources away from our operations. The outcome of any such litigation
is inherently uncertain. Even if we are successful, the litigation can be costly
in terms of dollars spent and diversion of management time.

     If a third party successfully claims an intellectual property right to
technology we use, it may force us to discontinue an important product or
product line, alter our products and processes, pay license fees, pay damages
for past infringement or cease certain activities. Under these circumstances, we
may attempt to obtain a license to this intellectual property; however, we may
not be able to do so on commercially reasonable terms, or at all. In addition,
regardless of the validity of such a claim, its mere existence may affect the
willingness of one or more customers to use or continue to use our products and,
thereby, materially impact us.

     Those companies with which we have entered or may enter into strategic
alliances encounter similar risks and uncertainties with respect to their
intellectual property. To the extent that any such alliance companies suffer a
loss or impairment of their respective technologies, we may suffer a
corresponding loss or impairment that may materially and adversely affect our
investments.

FOREIGN CURRENCY FLUCTUATIONS AND ECONOMIC AND POLITICAL CONDITIONS IN FOREIGN
COUNTRIES COULD CAUSE OUR REVENUES AND PROFITS TO DECLINE.

     In 2002, we derived approximately 50% of our product revenues from our
foreign operations. Our foreign operations generate sales and incur expenses in
local currency. As a result, we are exposed to market risk related to
unpredictable interest rates and foreign currency exchange rate fluctuations. We
recognize foreign currency gains or losses arising from our operations in the
period incurred. As a result, currency fluctuations between the U.S. Dollar and
the currencies in which we do business could cause our revenues and profits to
decline.

     Product revenues denominated in Euros accounted for approximately 34% of
total 2002 product revenues, and the fluctuations in the currency exchange rate
against the U.S. Dollar can have a significant impact on our reported product
revenues.

     We expect to continue to operate in foreign countries and that our
international sales will continue to account for a significant percentage of our
revenues. As such, we are subject to certain risks arising from our
international business



                                       24
<PAGE>


operations that could be costly in terms of dollars spent, the diversion of
management's time, and revenues and profits, including:

-     Difficulties and costs associated with staffing and managing foreign
      operations;

-     Unexpected changes in regulatory requirements;

-     Difficulties of compliance with a wide variety of foreign laws and
      regulations;

-     Changes in our international distribution network and direct sales forces;

-     Political trade restrictions and exchange controls;

-     Political, social, or economic unrest including armed conflict and acts of
      terrorism;

-     Labor disputes including work stoppages, strikes and embargoes;

-     Inadequate and unreliable services and infrastructure;

-     Import or export licensing or permit requirements; and

-     Greater risk on credit terms and long accounts receivable collection
      cycles in some foreign countries.

IF THE OWNERSHIP OF OUR COMMON STOCK CONTINUES TO BE HIGHLY CONCENTRATED, IT MAY
PREVENT OTHER STOCKHOLDERS FROM INFLUENCING SIGNIFICANT CORPORATE DECISIONS AND
MAY RESULT IN CONFLICTS OF INTEREST THAT COULD CAUSE OUR STOCK PRICE TO DECLINE.

     After our initial public offering and continuing to the present, Eastman
Chemical Company and Danisco A/S and their affiliates, referred to as our
majority stockholders, each own in excess of 40% of our outstanding common
stock. The majority stockholders will therefore have the ability, acting
together, to control fundamental corporate transactions requiring stockholder
approval, including the election of a majority of our directors, approval of
merger transactions involving us and the sale of all or substantially all of our
assets or other business combination transactions. The concentration of
ownership of our common stock may have the effect of either delaying or
preventing a change to our control favored by our other stockholders or
accelerating or approving a change to our control opposed by our other
stockholders. In addition, the majority stockholders' control over our
management could create conflicts of interest between the majority stockholders
and us with respect to the allocation of corporate opportunities and between the
majority stockholders and other stockholders.

IF EXISTING STOCKHOLDERS SELL LARGE NUMBERS OF SHARES OF OUR COMMON STOCK, OUR
STOCK PRICE COULD DECLINE.

     The market price of our common stock could decline as a result of sales by
our existing stockholders or holders of stock options of a large number of
shares of our common stock in the public market or the perception that these
sales could occur. Our two majority stockholders, for example, hold over 80% of
our common stock, and all of these shares are subject to registration rights. In
addition, we issued stock options to our officers, directors and employees
pursuant to our 2002 Omnibus Incentive Plan, approved by our stockholders in May
2002, and its predecessor plan.

OUR STOCK PRICE HAS BEEN, AND MAY CONTINUE TO BE, PARTICULARLY VOLATILE.


     The stock market from time to time, has experienced significant price and
volume fluctuations that are unrelated to the operating performance of
companies. The market prices for securities of biotechnology companies,
including ours, have been highly volatile in the period since our initial public
offering in July 2000 and may continue to be highly volatile in the future. Our
stock may be affected by this type of market volatility, as well as by our own
performance. The following factors, among other risk factors, may have a
significant effect on the market price of our common stock:

-     Developments in our relationships with current or future strategic
      partners;

-     Conditions or trends in the biotechnology industry;

-     Announcements of technological innovations or new products by us or our
      competitors;



                                       25
<PAGE>


-     Announcements by us or our competitors of significant acquisitions,
      strategic partnerships, joint ventures or capital commitments;

-     Developments in patent or other intellectual proprietary rights or
      announcements relating to these matters;

-     Investor concern regarding the public acceptance of the safety of
      biotechnology products or announcements relating to these matters;

-     Litigation or governmental proceedings or announcements relating to these
      matters;

-     Economic and other external factors or other disaster or crisis;

-     Future royalties from product sales, if any, by our licensees;

-     Sales of our common stock or other securities in the open market; and

-     Period-to-period fluctuations in our operating results.

WE EXPECT THAT OUR QUARTERLY RESULTS OF OPERATIONS WILL FLUCTUATE, AND THIS
FLUCTUATION COULD CAUSE OUR STOCK PRICE TO DECLINE, CAUSING INVESTOR LOSSES.

     A large portion of our expenses, including expenses for facilities,
equipment and personnel, are relatively fixed. Accordingly, if product revenue
declines or does not grow as we anticipate or non-product revenue declines due
to the expiration or termination of strategic alliance agreements or the failure
to obtain new agreements or grants, we may not be able to correspondingly reduce
our operating expenses in any particular quarter. Our quarterly revenue and
operating results have fluctuated in the past and are likely to do so in the
future. If our operating results in some quarters fail to meet the expectations
of stock market analysts and investors, our stock price would likely decline.
Some of the factors that could cause our revenue and operating results to
fluctuate include:

-     The ability and willingness of strategic partners to commercialize
      products derived from our technology or containing our products on
      expected timelines;

-     Our ability to successfully commercialize products developed independently
      and the rate of adoption of such products;

-     Fluctuations in consumer demand for products containing our technologies
      or products, such as back to school sales of blue jeans and other denim
      products, resulting in an increase in the use of textile processing
      enzymes, and fluctuations in laundry detergent use due to promotional
      campaigns run by consumer products companies; and

-     Fluctuations in geographic conditions including currency and other
      economic conditions such as economic crises in Latin America or Asia and
      increased energy and related transportation costs.

      We also have incurred significant infrequently occurring charges within
given quarters, such as those incurred in conjunction with restructuring
activities, and recognized investment income from sales of available-for-sale
marketable securities.

CONCERNS ABOUT GENETICALLY ENGINEERED PRODUCTS COULD RESULT IN OUR INABILITY TO
COMMERCIALIZE PRODUCTS.


     We produce a significant amount of our products from genetically modified
microorganisms. We cannot predict public attitudes and acceptance of existing or
future products made from genetically modified microorganisms. As a result, if
we are not able to overcome the ethical, legal and social concerns relating to
safety and environmental hazards of genetic engineering, the general public may
not accept our products and this may prevent us from commercializing products
dependent on our technologies or inventions. In addition, public attitudes may
influence laws and regulations governing the ownership or use of genetic
material, which could result in greater government regulation of genetic
research and bioengineered products.



                                       26
<PAGE>


IF WE ARE SUBJECT TO A COSTLY PRODUCT LIABILITY DAMAGE CLAIM OR AWARD, OUR
PROFITS COULD DECLINE.

     We may be held liable if any product we develop, or any product that a
third party makes with the use or incorporation of any of our products, causes
injury or is found otherwise unsuitable during product testing, manufacturing,
marketing or sale. Our current product liability insurance may not cover our
potential liabilities. Inability to obtain sufficient insurance coverage in the
future at an acceptable cost or otherwise to protect against potential liability
claims could prevent or inhibit the commercialization of products developed by
us or our strategic partners. If a third party sues us for any injury caused by
our products, our liability could exceed our insurance coverage amounts and
total assets and our profits could decline.

IF WE ARE SUBJECT TO COSTLY ENVIRONMENTAL LIABILITY DUE TO THE USE OF HAZARDOUS
MATERIALS IN OUR BUSINESS, OUR PROFITS COULD DECLINE.

     Our research and development processes involve the controlled use of
hazardous materials, including chemical, radioactive and biological materials.
Our operations also generate potentially hazardous waste. We cannot eliminate
entirely the risk of contamination or the discharge of hazardous materials and
any resultant injury from these materials. Federal, state, local and foreign
laws and regulations govern the use, manufacture, storage, handling and disposal
of these materials. Third parties may sue us for any injury or contamination
that results from our use or the third party's use of these materials. Any
accident could partially or completely shut down our research and manufacturing
facilities and operations. In addition, if we are required to comply with any
additional applicable environmental laws and regulations, we may incur
additional costs, and any such current or future environmental regulations may
impair our research, development or production efforts.

IF WE FAIL TO ATTRACT AND RETAIN QUALIFIED PERSONNEL, WE MAY NOT BE ABLE TO
ACHIEVE OUR STATED CORPORATE OBJECTIVES.

     Our ability to manage our anticipated growth, if realized, effectively
depends on our ability to attract and retain highly qualified executive officers
and technology and business personnel. In particular, our product development
programs depend on our ability to attract and retain highly skilled researchers.
Competition for such individuals is intense. If we fail to attract and retain
qualified individuals, we will not be able to achieve our stated corporate
objectives.


ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

     The information presented in Item 2 of Part I of this Report on Form 10-Q
under the heading "Market Risk" is hereby incorporated by reference.

ITEM 4. CONTROLS AND PROCEDURES

Quarterly Evaluation of the Company's Disclosure Controls and Internal Controls

     As of the end of the period covered by this report, the Company carried out
an evaluation, under the supervision and with the participation of the Company's
management, including Jean-Jacques Bienaime, the Company's Chairman, Chief
Executive Officer and President, and Raymond J. Land, the Company's Senior Vice
President and Chief Financial Officer, of the effectiveness of the design and
operation of the Company's disclosure controls and procedures (Disclosure
Controls) pursuant to Securities and Exchange Commission Rule 13a-15 under the
Securities Exchange Act of 1934 (Exchange Act). Based upon that evaluation, Mr.
Bienaime and Mr. Land concluded that the Company's disclosure controls and
procedures are effective in timely alerting them to material information
relating to the Company required to be included in the Company's periodic filing
with the Securities and Exchange Commission. There were no changes in the
Company's internal control over financial reporting that occurred during the
Company's most recent fiscal quarter that has materially affected, or is
reasonably likely to materially affect, the Company's internal control over
financial reporting.

Disclosure Controls and Internal Controls

     Disclosure Controls are procedures that are designed with the objective of
ensuring that information required to be disclosed in our reports filed under
the Exchange Act such as this Quarterly Report, is recorded, processed,
summarized and reported within the time periods specified in the Securities and
Exchange Commission's rules and forms. Disclosure Controls are also designed
with the objective of ensuring that such information is accumulated and
communicated to our management, including the Chief Executive Officer and the
Chief Financial Officer, as appropriate to allow timely decisions regarding


                                       27
<PAGE>



required disclosure. "Internal Controls" are procedures which are designed with
the objective of providing reasonable assurance that (1) our transactions are
properly authorized; (2) our assets are safeguarded against unauthorized or
improper use; and (3) our transactions are properly recorded and reported, all
to permit the preparation of our financial statements in conformity with
accounting principles generally accepted in the United States of America.

Limitations on the Effectiveness of Controls

     The Company's management does not expect that our Disclosure Controls or
our Internal Controls will prevent all error and all fraud. A control system, no
matter how well conceived and operated, can provide only reasonable, not
absolute, assurance that the objectives of the control system are met. Further,
the design of a control system must reflect the fact that there are resource
constraints, and the benefits of controls must be considered relative to their
costs. Because of the inherent limitations in all control systems, no evaluation
of controls can provide absolute assurance that all control issues and instances
of fraud, if any, within the Company have been detected. These inherent
limitations include the realities that judgments in decision-making can be
faulty, and that breakdowns can occur because of simple error or mistake.
Additionally, controls can be circumvented by the individual acts of some
persons, by collusion of two or more people, or by management override of the
control. The design of any system of controls also is based in part upon certain
assumptions about the likelihood of future events, and there can be no assurance
that any design will succeed in achieving its stated goals under all potential
future conditions; over time, control may become inadequate because of changes
in conditions, or the degree of compliance with the policies or procedures may
deteriorate. Because of the inherent limitations in a cost-effective control
system, misstatements due to error or fraud may occur and not be detected.



PART II. OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

            Nothing to report


ITEM 2. CHANGE IN SECURITIES AND USE OF PROCEEDS

            The information presented in Item 2 of Part I of this Report on Form
10-Q under the heading "Liquidity and Capital Resources" is hereby incorporated
by reference. The Company's Registration Statement on Form S-1 (Registration No.
333-36452) was effective as of July 27, 2000.


ITEM 3. DEFAULTS UPON SENIOR SECURITIES

            Nothing to report




                                       28
<PAGE>


ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

            The Annual Meeting of Stockholders of the Company was held on May
29, 2003. At that meeting, the stockholders elected directors and approved the
selection of PricewaterhouseCoopers LLP as independent auditors for the fiscal
year ended December 31, 2003. The total votes at the meeting were as follows:

(i)   To elect directors to serve a three-year term.

<TABLE>
<CAPTION>
                                                                                                 Votes
                                                                                ----------------------------------------
                              Nominee                                              For                         Withheld
                        ------------------------------                          ----------------------------------------
<S>                                                                             <C>                              <C>
                        Jean-Jacques Bienaime                                   57,374,593                       750,063

                        Bruce C. Cozadd                                         57,421,798                       702,858

                        Norbert G. Riedel                                       57,005,233                     1,119,423
</TABLE>


    There were no broker non-votes.

    Directors whose term in office continued after the meeting:

            Term expiring in 2004:  Theresa K. Lee, Robert H. Mayer, Jorgen
                                    Rosenlund

            Term expiring in 2005:  Soren Bjerre-Nielsen, Joseph A. Mollica,
                                    Gregory O. Nelson, James P. Rogers


(ii)  To approve the selection of PricewaterhouseCoopers LLP as independent
      auditors for the fiscal year ending December 31, 2003.

<TABLE>
<CAPTION>
                                                            Votes
                             --------------------------------------------------------------
                                 For                        Against                 Abstain
                             --------------------------------------------------------------
<S>                                                         <C>                     <C>
                             57,443,312                     355,056                 326,288
</TABLE>


                        There were no broker non-votes.


ITEM 5. OTHER INFORMATION

            Nothing to report





                                       29
<PAGE>



ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

   a.    EXHIBITS


<TABLE>
<CAPTION>
<S>      <C>         <C>
         (10)        Material Contracts
         ----        ------------------

                     +10.1        First Amendment to Supply Agreement by and
                                  between the Company and The Procter &
                                  Gamble Company entered into as of January
                                  1, 2003.

                     10.2         First Amendment to Research Agreement and
                                  Technology Transfer Agreement by and between
                                  the Company and The Procter & Gamble Company
                                  entered into as of June 23, 2003.

         (31)        Rule 13a-14(a)/15d-14(a) Certifications
         ----        ---------------------------------------

                     31.1         Rule 13a-14(a)/15d-14(a) Certifications

         (32)         Section 1350 Certifications
         ----        ---------------------------

                     32.1         Section 1350 Certifications

                     -------------------------------------------------

          +          Confidential Treatment requested as to certain
                     information, which has been separately filed with the
                     Securities and Exchange Commission pursuant to an
                     application for such treatment.
</TABLE>


   b.    REPORTS ON FORM 8-K

         On May 1, 2003 the Company filed a Current Report on Form 8-K
         regarding its press release concerning financial results for the first
         quarter of 2003. The report included condensed financial statements
         and other financial information.





                                       30
<PAGE>

                                   SIGNATURES


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.



                                     GENENCOR INTERNATIONAL, INC.


August 13, 2003                      By: /s/ Raymond J. Land
------------------------                 --------------------------------------
Date
                                     Raymond J. Land
                                     Senior Vice President and
                                     Chief Financial Officer
                                     (Principal Financial Officer)





August 13, 2003                      By: /s/ Darryl L. Canfield
------------------------                 ---------------------------------------
Date
                                     Darryl L. Canfield
                                     Vice President and Corporate Controller
                                     (Chief Accounting Officer)




                                       31
<PAGE>

                                  EXHIBIT INDEX
<TABLE>
<CAPTION>

<S>         <C>
(10)        Material Contracts
----        ------------------

            +10.1       First Amendment to Supply Agreement by and between the
                        Company and The Procter & Gamble Company entered into as
                        of January 1, 2003.

            10.2        First Amendment to Research Agreement and Technology
                        Transfer Agreement by and between the Company and The
                        Procter & Gamble Company entered into as of June 23, 2003.

(31)         Rule 13a-14(a)/15d-14(a) Certifications
----         ---------------------------------------

             31.1       Rule 13a-14(a)/15d-14(a) Certifications

(32)         Section 1350 Certifications
----         ---------------------------

             32.1       Section 1350 Certifications

             -------------------------------------------------

+           Confidential Treatment requested as to certain information, which
            has been separately filed with the Securities and Exchange
            Commission pursuant to an application for such treatment.
</TABLE>




                                       32